These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 2604677

  • 1. Control of simulator sickness in an AH-64 aviator.
    Kroll JD.
    Aviat Space Environ Med; 1989 Dec; 60(12):1202-3. PubMed ID: 2604677
    [Abstract] [Full Text] [Related]

  • 2. Simulator sickness: a problem for Army aviation.
    Crowley JS.
    Aviat Space Environ Med; 1987 Apr; 58(4):355-7. PubMed ID: 3579825
    [Abstract] [Full Text] [Related]

  • 3. The time course of postflight simulator sickness symptoms.
    Baltzley DR, Kennedy RS, Berbaum KS, Lilienthal MG, Gower DW.
    Aviat Space Environ Med; 1989 Nov; 60(11):1043-8. PubMed ID: 2818393
    [Abstract] [Full Text] [Related]

  • 4. Transdermal therapeutic system scopolamine (TTSS), dimenhydrinate, and placebo--a comparative study at sea.
    Noy S, Shapira S, Zilbiger A, Ribak J.
    Aviat Space Environ Med; 1984 Nov; 55(11):1051-4. PubMed ID: 6508687
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of transdermal scopolamine against seasickness: a 3-day study at sea.
    Attias J, Gordon C, Ribak J, Binah O, Rolnick A.
    Aviat Space Environ Med; 1987 Jan; 58(1):60-2. PubMed ID: 3814034
    [Abstract] [Full Text] [Related]

  • 6. Use of a motion sickness history questionnaire for prediction of simulator sickness.
    Kennedy RS, Fowlkes JE, Berbaum KS, Lilienthal MG.
    Aviat Space Environ Med; 1992 Jul; 63(7):588-93. PubMed ID: 1616434
    [Abstract] [Full Text] [Related]

  • 7. Transdermal scopolamine in the prevention of motion sickness: evaluation of the time course of efficacy.
    Homick JL, Kohl RL, Reschke MF, Degioanni J, Cintron-Trevino NM.
    Aviat Space Environ Med; 1983 Nov; 54(11):994-1000. PubMed ID: 6651736
    [Abstract] [Full Text] [Related]

  • 8. The Republic of Singapore Navy's Scopoderm TTS study: results after 2,200 man-days at sea.
    How J, Lee PS, Seet LC, Tan PK.
    Aviat Space Environ Med; 1988 Jul; 59(7):646-50. PubMed ID: 3044323
    [Abstract] [Full Text] [Related]

  • 9. Using flight simulators aboard ships: human side effects of an optimal scenario with smooth seas.
    Muth ER, Lawson B.
    Aviat Space Environ Med; 2003 May; 74(5):497-505. PubMed ID: 12751576
    [Abstract] [Full Text] [Related]

  • 10. Three-years' experience of transdermal scopolamine: long-term effectiveness and side-effects.
    Shupak A, Gordon CR, Spitzer O, Mendelowitz N, Melamed Y.
    Pharmatherapeutica; 1989 May; 5(6):365-70. PubMed ID: 2594820
    [Abstract] [Full Text] [Related]

  • 11. Transderm scopolamine efficacy related to time of application prior to the onset of motion.
    Levy GD, Rapaport MH.
    Aviat Space Environ Med; 1985 Jun; 56(6):591-3. PubMed ID: 4015572
    [Abstract] [Full Text] [Related]

  • 12. Treatment of motion sickness in parabolic flight with buccal scopolamine.
    Norfleet WT, Degioanni JJ, Calkins DS, Reschke MF, Bungo MW, Kutyna FA, Homick JL.
    Aviat Space Environ Med; 1992 Jan; 63(1):46-51. PubMed ID: 1550533
    [Abstract] [Full Text] [Related]

  • 13. Prevention and treatment of space sickness in shuttle-orbiter missions.
    Graybiel A.
    Aviat Space Environ Med; 1979 Feb; 50(2):171-6. PubMed ID: 36067
    [Abstract] [Full Text] [Related]

  • 14. [Scopolamine plaster caused hallucination. Toxic psychosis in a 10-year-old boy caused by an agent against motion sickness].
    Björk M, Wettergren B.
    Lakartidningen; 1995 Feb 15; 92(7):638. PubMed ID: 7861858
    [No Abstract] [Full Text] [Related]

  • 15. [Motion sickness--causes, symptoms, therapy].
    von Baumgarten R, Reiser M.
    Verh Dtsch Ges Inn Med; 1989 Feb 15; 95():593-7. PubMed ID: 2690530
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Antimotion-sickness efficacy of scopolamine 12 and 72 hours after transdermal administration.
    Graybiel A, Cramer DB, Wood CD.
    Aviat Space Environ Med; 1982 Aug 15; 53(8):770-2. PubMed ID: 7181807
    [Abstract] [Full Text] [Related]

  • 20. I heard that the adhesive patch you can wear to prevent motion sickness is available again. Why was it taken off the market?
    Mayo Clin Health Lett; 1998 Mar 15; 16(3):8. PubMed ID: 9516375
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.